Moleculin Biotech, Inc. — Form 8-K
Filed September 18, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On September 15, 2026, Moleculin Biotech filed an 8-K reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates the company has received a delisting notice from its exchange. No specific remediation timeline, financial details, or counterparty information is disclosed in the available filing header and document metadata.
Why this rating
Delisting is existential risk for micro-cap ($8.8M). Loss of public market access threatens liquidity, financing ability, and investor base—potentially fatal for early-stage biotech.
Extracted items
Price action (we called it negative)
before filing · preread $0.77 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.